Zika Virus Vaccine Candidate from Canada
mRNA-based or DNA vaccine platform for Zika flavivirus prevention, in clinical stages. Fits HTS 3002.49.0050 as other virus culture-derived prophylactic product via biotech processes.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Classify as gene therapy if applicable; special USDA permits for vectors
• Document trial phase and IRB approval; frozen shipment standard